MedTrace Logo

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

NCT04873258 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-07-23

No results posted yet for this study

Summary

A generic screening study to establish structural and/or functional baselines of specific organs.

Conditions

  • Healthy
  • Fatty Liver
  • MASLD
  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Obesity and Obesity-related Medical Conditions

Interventions

DIAGNOSTIC_TEST

Bioimpedence Vector Analysis

Bioimpedence vector analysis

Sponsors & Collaborators

  • Richmond Pharmacology Limited

    collaborator INDUSTRY

  • Richmond Research Institute

    lead INDUSTRY

Principal Investigators

  • Jorg Taubel, MD · Richmond Pharmacology Limited

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04873258 on ClinicalTrials.gov